Gilmartin Group and Canale Communications represent Imago BioSciences, which has agreed to be acquired by Merck for $1.4B.

The South San Francisco-based company is a clinical-stage biopharma that develops treatments for bone marrow diseases.

“This agreement leverages Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat, which is currently in Phase 2 trials while providing important value for shareholders,” said Dr. Hugh Rienhoff, founder/CEO of Imago.

“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” added Robert Davis, Merck CEO.

Gilmartin Group’s Laurence Wells handles the investment community for Imago, while Canale Communications' Ian Stone works the media.